Clinical Trials Logo

Excessive Daytime Sleepiness clinical trials

View clinical trials related to Excessive Daytime Sleepiness.

Filter by:

NCT ID: NCT00642928 Completed - Parkinson's Disease Clinical Trials

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg, 10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of Parkinson's disease patients

NCT ID: NCT00620659 Terminated - Clinical trials for Sleep Apnea, Obstructive

Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of MK0249 in treating refractory excessive daytime sleepiness (EDS) in patients with Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) using nasal continuous positive airway pressure (nCPAP) therapy.

NCT ID: NCT00385437 Completed - Depression Clinical Trials

Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder

Start date: April 2003
Phase: Phase 2
Study type: Interventional

This concurrent, two-part study will: I) Using overnight sleep recordings, evaluate the short- and long-term sleep-promoting effects of the antidepressant mirtazapine (Remeron) in patients who have been prescribed this medication for major depressive disorder and sleep disruption. II) Investigate the psychomotor performance of depressed patients using driving simulation testing before and during treatment with mitrazapine.

NCT ID: NCT00228566 Completed - Narcolepsy Clinical Trials

Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess patient reported outcomes with armodafinil treatment in terms of improvement in sleepiness, satisfaction with treatment, impact on ability to engage in life activities (ie, daily or work and family and/or social activities), and effects on fatigue. Clinician ratings on patient response to armodafinil treatment will also be assessed.

NCT ID: NCT00228553 Completed - Narcolepsy Clinical Trials

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

Start date: May 2004
Phase: Phase 3
Study type: Interventional

A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder